Aeglea BioTherapeutics Overview
Latest PEG ratio for Aeglea BioTherapeutics: 3240.67 — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow3240.67
The PEG ratio measures a stock's valuation relative to its earnings growth rate. A PEG ratio below 1.0 may indicate that the stock is undervalued relative to its growth potential.
As of the most recent data, AGLE shows a PEG ratio of 3240.67. That is above the Healthcare sector average of 2.56. Scroll down for historical charts and peer comparison views.
The Healthcare sector average PEG ratio is about 2.56. Aeglea BioTherapeutics is at 3240.67, which is higher that average. That is roughly 126502.8% above the sector mean. Use the comparison chart on this page to see how AGLE stacks up against individual peers as well.
Investors watch AGLE's PEG ratio because it compresses price and fundamentals into one number that is easy to compare across companies and over time. Aeglea BioTherapeutics's latest reading is 3240.67. Combining that with growth, ROE, and debt metrics usually beats relying on a single multiple.
Besides this peg ratio page, Stockcircle has Aeglea BioTherapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect PEG ratio (currently 3240.67) with ownership activity and broader fundamentals.
The Healthcare average PEG ratio is about 2.56, while AGLE is at 3240.67. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
